ReviewNeuropsychiatric disease and treatment2026
Ketogenic Diet and Neurological Health: A Narrative Review with Natural Language Processing-Assisted Thematic Mapping Using BERTopic.
Review in Neuropsychiatric disease and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The ketogenic diet (KD) is an established therapy for drug-resistant epilepsy and is increasingly investigated across other neurological disorders. Objective: To provide an updated narrative synthesis of recent mechanistic and clinical evidence on KD across neurological disorders, including its therapeutic applications, potential mechanisms, and current evidence gaps, and to use BERTopic as a supplementary natural language processing tool to characterize major research themes and temporal changes in research emphasis. Methods: Literature published from 2021 to early 2026 was retrieved from Scopus, Web of Science, and PubMed. After deduplication and eligibility screening, 1017 records were included in BERTopic analysis. PubMedBERT, UMAP, HDBSCAN, and c-TF-IDF were used for thematic mapping; interpretation and evidence synthesis remained expert-guided. Temporal analyses were restricted to 2021-2025. Results: Seven thematic clusters were retained, with increased representation of gut-brain-axis-related publications after 2023. Narrative synthesis highlighted energy metabolism, mitochondrial function, oxidative stress, neuroinflammation, neurotransmitter regulation, and the gut-brain axis as major mechanistic domains. Clinical evidence was strongest for drug-resistant epilepsy, while findings for Alzheimer's disease and migraine were less mature and those for Parkinson's disease remained preliminary. Conclusion: KD is an established therapy for drug-resistant epilepsy and shows potential across other neurological disorders, particularly Alzheimer's disease and migraine. Its effects may involve energy metabolism, mitochondrial function, oxidative stress, neuroinflammation, neurotransmitter regulation, and the gut-brain axis. BERTopic-assisted mapping complemented the narrative synthesis by summarizing major research themes and temporal trends.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.